INTRODUCTION
T he targeted movement of immune cells to centers of inflammation is orchestrated by chemokines. the first chemokine was discovered approximately 20 years ago: cXc chemokine ligand 8 (cXcl8), still more commonly known as interleukin- 8 (il-8) . since then, more than 40 additional chemokines have been described and found to display 4 different conserved cysteine motifs, those of the c, cc, cXc, and cX3c type. 1 the first receptor matched to the cXc-type chemokine il-8 2,3 was baptized cXc-type chemokine receptor 1 (cXcr1). in the year after the identification of cXcr1, a second receptor for il-8 with 77% amino acid identity to cXcr1 was discovered and denominated cXcr2. 4 a hallmark of the chemokine receptors is their ligand promiscuity. thus, both cXcr1 and cXcr2 bind, apart from il-8, other cXc-type chemokines 5 with a glutamate-leucinearginine motif. thereof, gcP-2 (cXcl6) and naP-2 (cXcl7) are ligands for both cXcr1 and cXcr2, whereas gro-α (cXcl1), gro-β (cXcl2), gro-γ (cXcl3), and ena-78 (cXcl5) are specific for cXcr2. gro-α, the cXcr2-specific agonist employed in this study, binds cXcr2 with a K d value of 0.22 nm. 6 like its analog il-8, it is considered to be an inflammatory mediator that recruits and activates neutrophils. 7 like other chemokine receptors, cXcr1 and cXcr2 belong to the family of 7-transmembrane region g-protein-coupled receptors (gPcrs). gPcrs are the most frequently addressed drug targets in the pharmaceutical industry. 8 in case of the chemokine receptors, an antagonistic interference with chemokine-guided chemotaxis is envisioned to provide a promising anti-inflammatory approach. in recombinant systems, activation of cXcr2 induces ca 2+ mobilization, 6 inhibits forskolin-stimulated camP production, 6 and initiates chemotaxis. 9 in human neutrophils, chemotaxis and ca 2+ mobilization depend on pertussis toxin-sensitive signaling pathways. 10, 11 in recent years, high-throughput fluorescence microscopic imaging in combination with automated image analysis [12] [13] [14] [15] [16] has been introduced to the technology toolbox of drug discovery units in the pharmaceutical industry under the name of highcontent screening (hcs). in hcs assays, the biomolecules of interest are labeled with various small-molecule fluorophores or fluorescent proteins that may be monitored in parallel at different wavelengths. 17 image analysis software quantifies the redistribution of the fluorophore-labeled biomolecules as a consequence of a pharmacological effect. such image analysis depends on high-resolution fluorimetric imaging. in this context, confocal imaging has sometimes proven to be advantageous. 18, 19 in the transfluor technology, the redistribution of an arrestin-fluorescent protein (arr-fP) conjugate upon gPcr stimulation is monitored by hcs. 20, 21 the broad applicability of the transfluor approach is based on gPcr desensitization and has been demonstrated for numerous gPcrs. 22, 23 the latter process is mediated by gPcr kinases (grKs) and by arrestins ( Fig. 1 ; scheme of gPcr activation-dependent arrestin redistribution). grKs phosphorylate agonist-activated gPcrs on serine and threonine residues.
arrestins are cytoplasmic proteins that are recruited to the plasma membrane by grK-phosphorylated gPcrs. 24 arrestins then uncouple the gPcr from the cognate g-protein 25, 26 and target the desensitized receptors to clathrincoated pits for endocytosis. 27, 28 apart from this indirect influence on g-protein signaling by the physical interference with the gPcr-g-protein-coupling, arrestins have more recently been found to directly mediate g-protein-independent signaling. 29, 30 the latter mechanism regulates various aspects of cell motility, chemotaxis, apoptosis, and possibly other cellular functions through a rapidly expanding list of signaling pathways. classically, the arrestin redistribution assays employed Aequorea victoria-derived green fluorescent protein (gfP) as a fusion protein marker for the arrestin. 24 in this work, we also employed a recently developed mutant of the Entacmaea quadricolor fluorescent protein eqfP611 31 fused to arrestin. the eqfP611 variant carries mutations 32, 33 that break the wild-type tetrameric fluorescent protein (fP) complex down into a dimer and result in a functional expression at 37 °c. two copies of the protein were fused to produce a tandem dimer construct (td-rfP611), suitable as a pseudo-monomeric label. td-rfP611 displayed favorable properties for hcs. in contrast to enhanced green fluorescent protein (egfP), td-rfP611 possesses a farred emission spectrum with less test compound interference as well as a large stokes shift. further advantageous properties are a high fluorescence brightness, photostability, and stability with regard to the fixation using formaldehyde. 33 interestingly, the two fusion proteins of arrestin with the two different fPs responded differently to the presence of overexpressed cXcr2 in the same cells. the redistribution of arr-td-rfP611 to endosomes depended on agonistic activation of cXcr2. in contrast, arr-egfP displayed a steady-state association with endocytic vesicles in cXcr2-expressing u2os cells that we suggest to be due to a constitutive activity of the receptor. in support of this hypothesis, we found the known cXcr2 antagonist sch527123 34 to act as an inverse agonist with respect to arr-egfP redistribution. the combined information from the two cXcr2-dependent arrestin redistribution assays employing either arr-td-rfP611 or arr-egfP enables the characterization of cXcr2 ligands with regard to agonism, neutral antagonism, and inverse agonism.
MATERIALS AND METHODS

Materials
recombinant human gro-α (chm-329B) was from Biotrend chemikalien gmbh (Köln, germany). fmat-Bluelabeled human gro-α (4314053c) was from applied Biosystems (applera deutschland gmbh, darmstadt, germany). Bovine serum albumin (Bsa; a3059), saponin (s4521), and formaldehyde (37%; 25.254-9) were from sigma-aldrich (st. louis, mo).
fetal calf serum (fcs; 10500-064), gentamicin (15750-037), penicillin/streptomycin (15070-063), trypsin-edta (1×) (25300-054), trypsin/versene (306-00580), l-glutamine (25030-123), and phosphate-buffered saline (PBs; 14190-094) were purchased from invitrogen (carlsbad, ca). furthermore, 10× hank's buffered salt solution (hBss; 14065-049), 1 m FIG. 1. scheme of the g-protein-coupled receptor (gPcr) agonistinduced arrestin-fluorescent protein (arr-fP) redistribution. agonist a activates a gPcr. a gPcr kinase (grK) phosphorylates the gPcr on its carboxy-terminal tail. (1) arr-fP is recruited to the plasma membrane by the grK-phosphorylated gPcr. (2) arr-fP then targets the gPcr to clathrin-coated pits for endocytosis. depending on the stability of the specific gPcr-arrestin interaction, the arr-egfP is either (3a) released after the formation of clathrincoated pits or (3b) cointernalized with the gPcr-loaded vesicles.
4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid (hePes;
15630-056), sodium bicarbonate solution (7.5%; 25080-060), hoechst 33342 (10 mg/ml, h3570), hygromycin B (10687-010), and zeocin (r250-05) were from invitrogen. the cXcr2 antagonist sch527123 was provided by the compound logistics group of Bi Pharma gmbh & co. Kg (Biberach, germany).
the murine monoclonal anti-cXcr2 antibody (maB331) was purchased from r&d systems (minneapolis, mn). an alexa-fluor-647 (af647)-labeled goat-anti-mouse antibody (a-21236) was from invitrogen. the in cell analyzer 3000 was from ge healthcare Biosciences (little chalfont, uK). the Qehs-type (i.e., quadrupole excitation high sensitive) opera hcs reader was from evotec technologies (hamburg, germany; now part of Perkinelmer life and analytical sciences, Waltham, ma).
Bd 384-well plates (35 0504) for imaging with the in cell analyzer 3000 were purchased from Becton dickinson (Bd; franklin lakes, nJ). for imaging with the opera hcs reader, cellcarrier 384-well plates (781056) were purchased from greiner Bio-one gmbh (frickenhausen, germany). all other materials were of the highest grade commercially available.
Cells and cell culture
cell culture flasks were purchased from nunc (178883; nalge nunc international corp., rochester, nY). a human osteosarcoma cell line (u2os; american tissue culture collection [atcc] number htB-96) was obtained from the atcc (manassas, va). a u2os cell line stably transfected with arr-egfP-encoding cdna was a kind gift of molecular devices (now part of mds analytical technologies, concord, on, canada). u2os cells were cultured with earle's minimum essential medium (earle's mem; f0325) from Biochrom ag (Berlin, germany), supplemented with 10% fcs, 1% penicillin/streptomycin, 4 mm l-glutamine, and 10 mm hePes. for the u2os cells stably expressing arr-egfP, 10 µg/ml gentamicin was added to the medium. the chinese hamster ovary (cho)-K1 cell line recombinantly expressing gα 16 was from molecular devices (sunnyvale, ca). the cho-K1/gα 16 cells were stably transfected with human cXcr2. the cho-K1/gα 16 /cXcr2 cells were cultured in ham's f12 medium (Be12-615f; cambrex, east rutherford, nJ), supplemented with 10% fcs, 1% penicillin/streptomycin, 2 mm l-glutamine, 0.2 mg/ml hygromycin B, and 2.5 mg/ml zeocin.
Vector construction
the human cXcr2 wild-type (wt) dna was in a pcdna3.1 vector. the d143v mutant of cXcr2 was generated by using the Quikchange  site-directed mutagenesis Kit (200518) from stratagene (la Jolla, ca) according to the manufacturer's protocol. for the Pcr amplification of rat β-arrestin 2 (gen Bank accession number m91590), the Platinum  high fidelity taq dna Polymerase (11304-011) from invitrogen was used. Processed Pcr products or digested dna fragments were purified using the Jetquick gel extraction Kit (420050) or the Jetquick Pcr Purification Kit (410050) from genomed gmbh (löhne, germany). the restriction enzymes Xhoi (r0146s), Xbai (r0145t), and apai (r0114s) as well as the t4 dna ligase (m0202s) were purchased from new england Biolabs (ipswich, ma). the restriction enzymes sali (10348783001), hindiii (10656313001), and Kpni (10742 945001) were from roche diagnostics gmbh (mannheim, germany). Plasmid dna propagated in Escherichia coli Xl2-Blue ultracompetent cells (200150; stratagene) was purified using the hispeed Plasmid midi Kit (12643) from Qiagen (hilden, germany).
for the generation of the fusion construct with arrestin, the coding sequence of td-rfP611 was subcloned with Xhoi/apai (new england Biolabs) from pcdna3-td-rfP611 33 into the vector pBi-14 (clontech, mountain view, ca). the cdna of egfP was amplified by Pcr and inserted into the Xhoi/Xbai sites of pBi-14. afterwards, the open reading frame of β-arrestin 2 was amplified by Pcr and inserted into the sali/Kpni sites of pBi-14-td-rfP611 or the hindiii/Kpni sites of pBi-14-egfP. the resulting cdnas encode for the fusion proteins β-arrestin 2-gYle-td-rfP611 and β-arrestin 2-gYle-egfP. Pcrmediated cloning was verified by dna sequencing at a commercial facility (mWg Biotech ag, ebersberg, germany).
CXCR2 internalization assay based on immune staining after fixation
a basic protocol for a chemokine receptor internalization assay has been published elsewhere. 35 We adapted this protocol to cXcr2 using the following modifications. Briefly, the cXcr2-expressing cho/gα 16 cells were plated into Bd 384well assay plates (aPs) using a multidrop 384 dispenser (thermo electron corp., Waltham, ma) with a cell density of 3000 cells/well in 30 µl/well of ham's f12 medium supplemented with 10% fcs, 0.2 mg/ml hygromycin B, 1% penicillin/streptomycin, 2 mm l-glutamine, and 2.5 mg/ml zeocin. after overnight incubation, the cells were washed with assay buffer (1x hBss, 0.0375% sodium bicarbonate, 10 mm hePes, ph 7.4), leaving 20 µl/well after the last wash cycle. then, 10 µl/well assay buffer supplemented with 0.1% Bsa was added to the aP using a multidrop 384 dispenser. sch527123 in 100% dmso was diluted by a factor of 1:200 in assay buffer into a compound buffer dilution plate (cBdP) using the cyBi-Well 384 simultaneous pipettor (cyBio ag, Jena, germany). then, 10 µl/well of the diluted test compound was transferred from the cBdP to the aP using again the cyBi-Well 384 simultaneous pipettor to the indicated final concentrations. the aP was incubated for 20 min at room temperature (rt). then, 10 µl/well of 75 nm gro-α in assay buffer was added. Wells without test compound or agonist but containing assay buffer supplemented with 0.1% dmso served as a vehicle control. Wells without test compound but containing a final concentration of 15 nm gro-α in assay buffer supplemented with 0.1% dmso served as stimulated control. the aPs were then incubated for the indicated time periods or for 30 min in the final protocol at 37 °c and 5% co 2 in a humidified incubator. for the gro-α ec 50 determination, test compound was omitted and gro-α was added to the indicated final concentrations.
formaldehyde fixation, staining of the nuclei with hoechst 33342, permeabilization, Bsa blocking, and immune staining were carried out as described before, using a 1:10,000 dilution of the anti-cXcr2 antibody and a 1:1000 dilution of the af647-conjugated anti-mouse antibody. imaging with the in cell 3000 analyzer was performed using the 364-nm laser line for fluorescence excitation of the hoechst 33342 dye and the 647-nm laser for the af647/cXcr2 signal.
Arrestin redistribution assays
the transfluor experiments were conducted under a labeling license from molecular devices. u2os cells were transiently cotransfected with plasmid encoding arr-td-rfP611 or arr-egfP together with plasmid encoding cXcr2 or the d143v mutant of cXcr2 using the nucleofector device and the cell nucleofector kit v from amaxa, inc. (gaithersburg, md) according to the manufacturer's instructions. u2os cells stably expressing arr-egfP were transiently transfected with only plasmid encoding either cXcr2 or the cXcr2 d143v mutant using the same device and transfection kit. optimization and upscaling of the transient transfection protocol were conducted with increasing numbers of u2os or arr-egfP/ u2os cells in a single nucleofector cuvette using an egfP construct (data not shown). all in all, two electroporation reactions were enough to produce the transfected cells for twelve 384-well aPs (corresponding to 4608 data points). the egfP-optimized transfection rates for egfP (between 40% and 60%) were also found for the arr-fP and/or the cXcr2 constructs.
after transfection, the cells were plated into the aP (i.e., a Bd 384-well plate for imaging with the in cell analyzer 3000, a cellcarrier 384-well plate for imaging with the opera) using a multidrop 384 dispenser with a cell density of 5000 cells/well in 40 µl/well of earle's mem supplemented with 10% fcs, 1% penicillin/streptomycin, 4 mm l-glutamine, and 10 mm hePes.
the translocation assays were conducted at 48 h after the transient transfection. for this purpose, the cells were washed 3 times using a Bio-tek elx405 ht microplate washer (Biotek instruments, Winooski, vt) with 80 µl wash buffer (1× hBss, 0.0375% sodium bicarbonate, 10 mm hePes, ph 7.4) per well and cycle, leaving 20 µl/well after the last wash cycle. after the washing step, the two following alternative assay protocols were applied as indicated.
(1) for the experiments omitting the agonist gro-α, 20 µl/ well assay buffer supplemented with 0.1% Bsa was added to the aP. sch527123, dissolved in 100% dmso, was diluted by a factor of 1:200 in assay buffer, and 10 µl/well of the diluted solution was transferred to the aP, resulting in the indicated final concentrations of sch527123 with a residual 0.1% dmso. the cells were incubated for the indicated time periods at 37 °c and 5% co 2 in a humidified incubator and then fixed for 30 min at rt with 4% formaldehyde supplemented with 1 µm hoechst 33342.
(2) for the determination of the ic 50 values in the presence of gro-α (15 nm) or of the ec 50 values for gro-α, 10 µl/well assay buffer supplemented with 0.1% Bsa was added to the aP after the above-described washing step. after the addition of 10 µl/well sch527123 (or of the vehicle control) in assay buffer diluted to the indicated final concentrations, the aP was incubated for 30 min at rt. then, 10 µl/well of gro-α in assay buffer with 0.1% Bsa was added to the indicated final concentrations. all wells (including the vehicle control wells) contained a final, residual concentration of 0.1% dmso. after an incubation time of 30 min at 37 °c and 5% co 2 in a humidified incubator, the cells were fixed using 4% formaldehyde, and the nuclei were stained using hoechst 33342 as described above.
after 3 washing cycles, the plates were subjected to immunofluorescence staining as described 35 using murine anti-cXcr2 antibody and an af647-conjugated anti-mouse antibody. imaging with the in cell 3000 analyzer was performed using the 364-nm laser line for fluorescence excitation of the hoechst 33342 dye, the 647-nm laser for the af647/ cXcr2 signal, and the 488-nm laser line for the arr-egfP signal, combined with the following fluorescence emission band-pass filters: 450 nm/full-width at half maximum (fWhm) transmission of 65 nm, 695 nm/(fWhm) 55 nm, and 535 nm/ (fWhm) 45 nm, respectively. Because the in cell analyzer 3000 does not provide a laser line suitable for fluorescence excitation of td-rfP611, the respective imaging was conducted with the opera using the 561-nm laser line for the arr-td-rfP611, the 405-nm laser line for the hoechst 33342 dye, and the 635-nm laser line for the af647/cXcr2 signal, combined with the following fluorescence emission band-pass filters: 600 nm/(fWhm) 40 nm, 450 nm/(fWhm) 50 nm, and 690 nm/(fWhm) 40 nm, respectively. like other hcs formats, the transfluor assay may be adapted to higher throughput 18, 36 but is generally used as a secondary assay due to the relatively high costs and due to the often more complex assay protocols. With regard to the cost per well of the transfluor assay, the transfluor licensing fee, imaging-suitable microplates, and-in our particular case-the cost for the transient transfection reagents and for the anti-cXcr2 immune staining antibodies have to be considered. likewise, the throughput of our arrestin redistribution assay was limited by the transient transfection procedure and the anti-cXcr2 immune staining protocol. however, after 48 h, the 12 aPs were further processed within 6 h, including compound dilution and transfer, incubation times, and staining procedures.
Live-cell imaging
cells were transiently transfected, seeded into aP wells, incubated, and washed as described above for the fixed cell experiments, leaving 20 µl/well of wash buffer after the last wash cycle. then, 20 µl/well assay buffer supplemented with 0.1% Bsa and dmso to a final concentration of 0.1% was added to the respective wells. low-intensity nuclear staining was performed by adding 10 µl of hoechst 33342 to a final concentration of 200 nm for 30 min prior to the first imaging. for live monitoring of arrestin and gro-α translocation kinetics on the single cell level, imaging was carried out using the climate chamber function of the opera (37 °c/5% co 2 /80% relative humidity). imaging was done immediately before and at the indicated time points after the addition of fmat-Bluelabeled human gro-α (10 nm) or sch527123 (1 µm) using the same laser/fluorescence emission filter combinations as described above or the 488-nm laser for arr-egfP combined with the 540 nm/(fWhm) 75-nm band-pass emission filter. in addition, where investigated, the 635-nm laser line combined with the 690 nm/(fWhm) 40-nm band-pass emission filter was employed for the fmat-Blue signal.
Image analysis
(1) Using the Acapella 2.0 software. to quantify arrestin redistribution using the acapella 2.0 software (evotec technologies/Perkinelmer), nuclei were detected and cell borders simulated, selecting the cells that expressed both cXcr2 and arr-fP fusion proteins beyond defined fluorescence emission thresholds. for these cells, the fluorescence emission associated with arr-fP granules of a predefined size/shape and fluorescence intensity range was quantified.
(2) Using the IN Cell Analyzer 3000 granularity algorithm. for the internalization/arrestin redistribution assays based on fluorimetric imaging by the in cell analyzer 3000, images were analyzed using the granularity (grn2) algorithm (image analysis software supplied together with the in cell analyzer 3000). Briefly, the grn2 algorithm identified the nuclei as pixel accumulations above a specified intensity threshold in the blue (nuclear) channel image. in a specified dilated "cytoplasmic" mask region around these nuclei, grains of a predefined size and intensity corresponding to the internalized receptor or arrestin were identified. in the arrestin redistribution applications, the grn2 algorithm also allowed us the introduction of a minimum intensity threshold for the cXcr2 signal. the fgrain value was calculated as below: fgrain = sum of pixel brightness values in test boxes corresponding to valid grains ____________________________________________________________ × 1000 sum of pixel brightness values in dilated mask region .
EC 50 determination and statistical data analysis
using the graph Pad Prism software version 3.00 or a company-internal high-throughput screening (hts) application, dose-response curves were fitted to the following equation:
where x is the concentration of the test compound, and hill indicates the hill coefficient.
Z′ values were calculated as described previously 37 :
3 sd high + 3 sd low Z´ = 1 -_________________ mean high -mean low .
[ 35 S]GTPγS binding
cXcr2-mediated binding of guanosine 5′-o(3-[ 35 s]thiotriphosphate) to membranes of baculovirus-infected insect cells was assayed as described. 38 in brief, membranes from insect cells expressing either human cXcr2 39 or human cXcr4, 40 together with rat g i α 2 , human gβ 1 , and bovine gγ 3 (10 µg of protein per sample), were incubated for 60 min at 30 ºc in a mixture (100 µl) containing 50 mm triethanolamine-hcl (ph 7.4), 1 mm edta, 50 mm nacl, 3 µm guanosine diphosphate (gdP), and 0.6 nm [ 35 s]gtPγs (1250 ci/mmol). the incubation was terminated by rapid filtration through 0.45-µm pore size nitrocellulose membranes. the membranes were washed and dried, and the retained radioactivity was determined by liquid scintillation counting. nonspecific binding was defined as the binding not competed for by 60 µm nonlabeled gtPγs.
RESULTS
CXCR2-ligand-modulated arrestin trafficking
for the establishment of a functional assay allowing the determination of cXcr2-dependent arrestin redistribution, two different arrestin-fluorescent-protein (arr-fP) conjugates were investigated as biosensors for detecting cXcr2 activation. on one hand, we applied egfP-tagged arrestin (arr-egfP), a well-established component of the transfluor assay technology, 24 by using a u2os cell line stably expressing this protein. in this case, the experiments were performed after transient transfection of the cell line with a cdna encoding human cXcr2. on the other hand, we created a new arr-fP-chimera by using the Entacmaea-derived red fluorescent protein td-rfP611 for the visualization of arrestin trafficking at longer wavelengths with less test compound interference in comparison to egfP. in this context, the cXcr2-agonist-dependent translocation of td-rfP611-tagged arrestin was evaluated after transient cotransfection of native u2os cells with cdnas encoding the receptor and arr-td-rfP611. Figure 2 shows that both the td-rfP611 (false color: green) and the egfP (shown in green) fusions with arrestin at ~200 × ic 50 (i.e., 1 µm). the cells were fixed using 4% formaldehyde, the nuclei were stained with hoechst 33342, and the cells were permeabilized and immune stained for cXcr2. (A-C) imaging was conducted with the opera using the 405-nm laser for hoechst 33342 (blue), the 561-nm laser for arr-td-rfP611 (false color: green), and the 635-nm laser for the murine anti-cXcr2 mab in complex with goat-anti-mouse-af647 (red). (D-F) imaging was conducted with the in cell analyzer 3000 using the 364-nm laser line for hoechst 33342 (blue), the 488-nm laser line for arr-egfP (green), and the 647-nm laser for the murine anti-cXcr2 mab in complex with goat-anti-mouse-af647 (red). White arrowheads indicate the attachment of arr-fP to large endosomal vesicles. accumulated together with the immunolabeled cXcr2 (shown in red) in large perinuclear endocytic vesicles after treatment of cells with the chemokine gro-α for 30 min ( Fig. 2A and D, respectively) . in contrast, in cells expressing only little or no cXcr2, the two fluorescent proteins showed a rather uniform distribution across the cytosol irrespective of gro-α treatment ( Fig. 2A,B and D,E) .
surprisingly, distinct cellular distribution patterns were observed for the two fluorescent arrestin conjugates in the absence of gro-α ( Fig. 2B,E) . thus, cells expressing cXcr2 and arr-td-rfP611 ( Fig. 2B) presented only little intracellular granular staining for the arrestin conjugate and the receptor: the former was rather homogeneously distributed across the cytoplasm, and the latter displayed an enrichment at the plasma membrane. in contrast, cells expressing cXcr2 and arr-egfP ( Fig. 2E) revealed a marked accumulation of arrestin in the proximity of the nuclei, similar to the gro-α-treated cells expressing these two proteins (Fig. 2D) . this distribution of arr-egfP, solely dependent on the presence of unoccupied cXcr2 in the same cells, indicates constitutive activity of cXcr2. treatment of arr-td-rfP611-expressing cells with the cXcr2 antagonist sch527123 had only minor effects on the localization of arr-td-rfP611 (Fig. 2C) . on the contrary, the intracellular distribution of the arr-egfP fusion protein was strikingly altered (Fig. 2F) . thus, the cells treated with sch527123 displayed a rather uniform distribution of arr-egfP in the cytosol, independent of the presence or absence of cXcr2. the next experiment was designed to examine the effect of sch527123 on the distribution of arr-egfP in live rather than fixed cells expressing cXcr2 (Fig. 3) . to this end, the climate chamber function of the opera was used. representative cells, imaged prior to addition of sch527123, showed constitutive accumulation of arr-egfP in cytoplasmic granules (Fig. 3A) . already at the 3-min time point after the addition of 1 µm sch527123, this distribution pattern of arr-egfP was completely reversed (Fig. 3B) . no further effects of sch527123 were observed over the next 1 h (images not shown), suggesting a stable inhibition of the constitutive cXcr2 activity over this time period. these results indicated that sch527123 acted as an inverse agonist of cXcr2 and thereby reduced the constitutive activity of cXcr2 with regard to arr-egfP trafficking.
Live single-cell imaging of Gro-α internalization and Gro-α-mediated arrestin redistribution
to examine and compare the kinetics of gro-α-mediated redistribution of arr-egfP versus arr-td-rfP611 in live cells, time course experiments were performed, again using the climate chamber function of the opera (Figs. 4-6) . in order to concurrently detect the redistribution of cXcr2, u2os cells expressing cXcr2 and the respective arr-fP fusion protein were exposed to 10 nm fmat-Blue-labeled human gro-α. consistent with the results shown in Figure 3 , arr-egfP was FIG. 3. redistribution of arr-egfP after treatment with sch527123 determined by live-cell imaging. u2os/arr-egfP cells were transiently transfected with plasmid encoding cXcr2. live-cell imaging was conducted in the environmental chamber of the opera at 37 °c, 80% relative humidity, and 5% co 2 using the 364-nm laser line for hoechst 33342 (blue) and the 488-nm laser line for arr-egfP (green). the left image (A) was taken before addition of the inverse agonistic sch527123, and the right image (B) was taken 3 min after addition of sch527123 at ~200 × ic 50 (i.e., 1 µm). detected in granular structures already prior to addition of the fluorescently labeled ligand (Fig. 4, center left) . however, analysis of the images obtained at later time points revealed that these granular structures were limited to cells capable of binding and internalizing fmat-Blue-gro-α and, therefore, expressing cXcr2. importantly, the granular pattern of arr-egfP distribution remained virtually constant in cXcr2expressing cells over the 30-min time course of the experiment. this was apparent despite the ongoing fmat-Blue-groα-mediated cXcr2 activation in these cells, evidenced by an fmat-Blue-gro-α cell surface binding and accumulation in intracellular granules.
in the case of arr-td-rfP611-expressing cells (Fig. 5) , no constitutive accumulation of arrestin could be detected prior to the addition of fmat-Blue-gro-α (i.e., at time 0 [center left]). Plasma membrane binding of the labeled chemokine was already observed at the 3-min time point (upper left). this was considerably earlier than observed for the cXcr2/ arr-egfP-expressing cells, where fmat-Blue-gro-α binding was only detectable at the 18-min time point (Fig. 4) . in addition, the labeled chemokine was internalized in arr-td-rfP611-expressing cells much more rapidly than in arr-egfP-expressing cells. thus, binding of fmat-Bluegro-α and internalization of the liganded receptor correlated well with the accumulation of the arrestin fusion protein in cells coexpressing arr-td-rfP611. conversely, in cells expressing arr-egfP, this accumulation appeared to occur independently of chemokine agonist-mediated cXcr2 activation. Figure 6 shows that fmat-Blue-gro-α ultimately colocalized with both arr-fP chimeras in the larger endosomal structures evident on the enlarged images obtained 30 min (arr-egfP) and 12 min (arr-td-rfP611), respectively, after the addition of the labeled receptor ligand. thus, in both cases, gro-α-activated cXcr2 apparently remained associated with arrestin beyond the clathrin-coated pit stage, defining cXcr2 as a "vesicle former"-type gPcr. 41, 42 
Concentration dependency of Gro-α-and Sch527123mediated effects on arrestin redistribution and CXCR2 internalization
next, the concentration dependence of the effects of gro-α and sch527123 on arrestin redistribution and cXcr2 internalization was determined ( Figs. 7 and 8, Table 1 ). to this end, FIG. 4. time course of fmat-Blue-gro-α/cXcr2 and arr-egfP redistribution after fmat-Blue-gro-α stimulation determined by livecell imaging. u2os/arr-egfP cells were transiently transfected with plasmid encoding cXcr2. live-cell images were taken in the environmental chamber of the opera at 37 °c, 80% relative humidity, and 5% co 2 using the uv light source for hoechst 33342 (blue), the 635-nm laser for the fmat-Blue-gro-α (upper panel; red), and the 488-nm laser for arr-egfP (center panel; green). the lower image panel displays an overlay of the nuclear (blue), arrestin (green), and gro-α (red) signal. the "0 min" image was taken before addition of fmat-Blue-gro-α; all further images were taken at the indicated time points after addition of 10 nm fmat-Blue-gro-α. u2os cells recombinantly expressing cXcr2 and arr-td-rfP611 and cho cells expressing cXcr2 and gα 16 were treated with increasing concentrations of gro-α ( Fig. 7A,C) or gro-α at a fixed concentration (15 nm) and increasing concentrations of sch527123 (Fig. 7B,D) . the accumulation of arrtd-rfP611 and cXcr2 in intracellular granules was quantified using the appropriate image analysis algorithms. cho cells stably expressing cXcr2 were used rather than transiently transfected u2os cells in panels B and D because the relatively low cXcr2 expression in the latter cells precluded an immunochemical quantification of its accumulation in granular structures. Figure 7A ,C shows that gro-α caused arr-td-rfP611 accumulation and cXcr2 internalization with similar ec 50 values, 1.1 nm and 2.4 nm, respectively. the calculated Z′ value of arr-td-rfP611 accumulation was 0.62. at 15 nm gro-α, sch527123 antagonized gro-α-stimulated arrestin accumulation with an ic 50 value of 6.1 nm (Fig. 7B) and cXcr2 internalization with a virtually identical ic 50 value, 5.8 nm (Fig. 7D) . this result confirms that arrestin accumulation and receptor internalization were tightly correlated for arr-td-rfP611 and cXcr2, in line with prior literature results for other gPcrs (see introduction). consequently, cXcr2-mediated redistribution of the novel arr-td-rfP611 fusion of arrestin, as established in this study, can be used to quantitate agonism and neutral antagonism at this receptor. in u2os cells stably expressing arr-egfP and transiently transfected with cXcr2 cdna, a high level of constitutive arrestin accumulation was already observed in the absence of gro-α, and addition of gro-α up to 30 nm caused no further effect (Fig. 8A) . in the presence of 15 nm gro-α, sch527123 antagonized the arr-egfP redistribution with an ic 50 value of 5.8 nm (Fig. 8B) , which was virtually identical to the ic 50 values observed above for the arr-td-rfP611 redistribution (Fig. 7B) and for cXcr2 internalization (Fig. 7D) . When the latter experiment was conducted in the absence of gro-α (not shown), sch527123 also caused a complete loss of granular arr-egfP accumulation; the ic 50 value was 2.6 nm in this case. these findings are in accordance with the inverse agonistic activity of this compound suggested above. Based on the assay window between gro-α-stimulated and sch527123-suppressed arr-egfP redistribution, a Z′ value of 0.65 was calculated for the experiment shown in Figure 8B .
next, we examined whether constitutive accumulation of egfP-tagged arrestin is also observed in u2os cells transiently FIG. 5. time course of fmat-Blue-gro-α/cXcr2 and arr-td-rfP611 redistribution after fmat-Blue-gro-α stimulation determined by live-cell imaging. u2os cells were transiently transfected with plasmids encoding arr-td-rfP611 and cXcr2. live-cell imaging was performed in the environmental chamber of the opera at 37 °c, 80% relative humidity, and 5% co 2 using the uv light source for hoechst 33342 (blue), the 635-nm laser for the fmat-Blue-gro-α (upper panel; red), and the 561-nm laser for arr-td-rfP611 (center panel; green). the lower panel displays an overlay of the nuclear (blue), arrestin (green), and gro-α (red) signal. the "0 min" image was taken before addition of fmat-Bluegro-α; all further images were taken at the indicated time points after addition of 10 nm fmat-Blue-gro-α. transfected with both arr-egfP-and cXcr2-encoding cdnas (Fig. 8C) . there was no difference between cells with stable and transient expression of arr-egfP in constitutive accumulation of arr-egfP in the absence of gro-α and in the response to increasing concentrations of gro-α (cf. Fig. 8A,C) . likewise, the cells responded very similarly to increasing concentrations of sch527123 in the presence of 15 nm gro-α (Fig. 8B,D) . specifically, the ic 50 values determined for sch527123 were 5.8 nm and 6.5 nm, and the Z′ values were 0.65 and 0.55, respectively.
to establish the inverse agonistic properties of sch527123 in an arrestin-independent assay format, we tested binding of the poorly hydrolyzable gtP analog [ 35 s]gtPγs to membranes of baculovirus-infected insect cells expressing either cXcr2 or cXcr4 and heterotrimeric g i2 but no arr-fP fusion protein. in this experiment (Fig. 9) , high-affinity binding of [ 35 s]gtPγs was already evident in the absence of gro-α, and more important, sch527123 displayed an inverse agonistic effect in membranes from insect cells expressing cXcr2 and g i2 . the latter effect was similar to that observed above in the arrestin redistribution assays with an ic 50 value of 3.0 nm. in contrast, sch527123 had no effect on basal [ 35 s]gtPγs binding to membranes from insect cells expressing human cXcr4 and g i2 , confirming the receptor specificity of the compound's inverse agonistic effect.
Effects of mutational CXCR2 activation on arrestin redistribution
although the constitutive activity of wild-type (wt) cXcr2 confirmed in Figure 9 was apparently not sufficient to induce redistribution of arr-td-rfP611 (cf. Figs. 2, 5, and 7) , we FIG. 6. colocalization of fmat-Blue-gro-α/cXcr2 and arr-fP after fmat-Blue-gro-α stimulation in live cells. upper image panel A-C: u2os/arr-egfP cells were transiently transfected with plasmid encoding cXcr2. lower image panel D-F: u2os cells were transiently transfected with plasmids encoding arr-td-rfP611 and cXcr2. the cells were treated for (A-C) 30 min or (D-F) 12 min with 10 nm fmat-Blue-gro-α in the environmental chamber of the opera at 37 °c, 80% relative humidity, and 5% co 2 . for imaging, we used the uv light source for hoechst 33342 (blue), the 635-nm laser for the fmat-Blue-gro-α (red; A, D) , and either the 488-nm laser for arr-egfP or the 561-nm laser for arr-td-rfP611 (green; B, E). the right images (C, F) display overlays of the nuclear (blue), arrestin (green), and gro-α (red) signal. arrowheads indicate the colocalization of arrestin and fmat-Blue-gro-α in endosomal compartments.
found that a known constitutively active mutant of cXcr2 (d143v 43 ) caused a limited relocalization of arr-td-rfP611 in the absence of gro-α ( Fig. 10) . the cXcr2 d143v-induced constitutive redistribution of arr-td-rfP611 amounted to approximately 30% of the maximal arr-td-rfP611 redistribution at 15 nm gro-α. the cXcr2 d143v-dependent arr-td-rfP611 relocalization was fully reversed by addition of 1 µm sch527123 (not shown), as described above for groα-treated cXcr2 wt-expressing cells (cf. Fig. 7B ). When cXcr2 d143v was coexpressed with arr-egfP, a complete induction of arr-egfP redistribution was observed even in the absence of gro-α, as was the case for cXcr2 wt in this experiment and in the one presented in Figure 8 . in both cXcr2 wt-and cXcr2 d143v-expressing cells, addition of 15 nm gro-α caused no further effect. in agreement with the inverse agonist nature of sch527123, this compound (1 µm) caused full reversal of cXcr2 wt-and cXcr2 d143v-driven arr-egfP relocalization, both in the absence and in the presence of gro-α (15 nm; not shown).
DISCUSSION
With the first demonstration of constitutive (i.e., ligandindependent) activity of gPcrs, 44, 45 a new paradigm for possible pharmacological intervention was born: the "inverse agonist." an inverse agonist is defined as an antagonistic compound that . (B, D) the cells were treated for 20 min with the indicated concentrations of sch527123, then for 30 min with 15 nm gro-α. the cells were fixed using 4% formaldehyde, the nuclei were stained with hoechst 33342, and the cells were permeabilized and immune stained against cXcr2. images were taken until the number of cells detected per well exceeded 300. data points are the mean values ± sd for images taken from 8 microplate wells.
reduces the resting-state constitutive activity of a gPcr, whereas a neutral antagonist effect may only be detected in the presence of an agonist. experimentally, the acceptance of constitutive activity had long remained contentious due to the suspected presence of contaminating agonist molecules in the membrane receptor preparation or in the medium of the analyzed cells. 46 the cells were treated with (A, C) increasing concentrations of gro-α or gro-α at a fixed concentration (15 nm) and (B, D) increasing concentrations of sch527123. (A, C) the arrow indicates the fgrain value for the constitutively accumulated arr-egfP in vehicle-stimulated cells. after fixation with 4% formaldehyde and nuclear staining with hoechst 33342, the cells were permeabilized and immune stained against cXcr2. images were taken until the number of cells detected per well exceeded 300. data points are the mean values ± sd for images taken from 8 microplate wells. between neutral antagonists and inverse agonists (e.g., at the histamine h 3 receptor, 47 serotonin 5-ht 2 receptors, 48 or the β 1 adrenoceptor). 49 for this reason, there is a demand for suitable assay techniques to analyze inverse agonism with regard to pharmacologically relevant receptor signaling mechanisms. in this work, we applied two forms of arr-fP redistribution assays using (1) arr-egfP detecting constitutive activity of cXcr2 or (2) arr-td-rfP611 requiring gro-α-stimulated cXcr2 for arrestin redistribution. the arr-egfP transfluor assay allowed us to detect the inhibition of cXcr2 constitutive activity by the inverse agonist sch527123. our interpretation of the observed arr-egfP redistribution as a consequence of constitutive cXcr2 activity is supported by several pieces of evidence. thus, the known cXcr2 antagonist sch527123 was shown to also act as an inverse agonist in a cXcr2-modulated guanine nucleotide binding assay format with an ic 50 value similar to that found for the inhibition of arr-egfP redistribution. furthermore, transient expression of the d143v mutant of cXcr2, known to possess higher constitutive activity than the wild-type protein, was shown to also induce the redistribution of arr-td-rfP in a sch527123-sensitive manner.
constitutive redistribution of constitutively active cXcr2 in the presence of arr-egfP would explain the slower fmat-Blue-gro-α internalization kinetics observed in the arr-egfP-expressing cells (Fig. 4) . in this context, constitutively internalized cXcr2 would not be available at the cell surface for fmat-Blue-gro-α binding at time 0, and the fluorescent ligand could only accumulate in endosomes by a slower, constitutive recycling process. in contrast, at the lower constitutive cXcr2 internalization rate encountered in the arrtd-rfP611-expressing cells (Fig. 5) , higher levels of cXcr2 would be present at the cell surface at the 0-min time point. this would be consistent with the observation that colocalization of fmat-Blue-gro-α and arr-td-rfP611 was visible already at the earliest imaged time point (3 min) . the strong correlation between the kinetics of fmat-Blue-gro-α internalization and arr-td-rfP611 accumulation in granular structures and the close agreement of these process(es) with previous data on cXcr2 desensitization kinetics 50 are also consistent with this view. similar kinetics of desensitization have been observed for other relatively fast internalizing FIG. 10. effects of mutational cXcr2 activation on arrestin redistribution. u2os cells had transiently been cotransfected with the indicated arr-fP cdnas and with cdnas encoding either cXcr2 wt or d143v, as indicated. the cells were treated for 30 min with 15 nm gro-α or vehicle. afterwards, the cells were fixed using 4% formaldehyde, and the nuclei were stained with hoechst 33342. results for each combination of arr-fP and cXcr2 construct are normalized to cells treated with 15 nm gro-α (= 100%) and cells treated with 1 µm sch527123 (0%). ]gtPγs binding to membranes from g i2 -expressing cells is increased approximately 1.5-fold when binding is assayed on membranes from cells coexpressing cXcr2 or cXcr4 in the absence of cXc chemokines, thus allowing the determination of constitutive cXcr2 activity. the difference in basal [ 35 s]gtPγs binding between the two membrane preparations is likely due to different levels of cellular cXcr2 versus cXcr4 expression obtained in this experiment. gPcrs, for example, the endothelin a receptor and the β 2 adrenoreceptor (β 2 ar). 51, 52 Why did arr-egfP, in contrast to arr-td-rfP611, respond to the constitutive activity of cXcr2? theoretically, the expression levels of the two arr-fP fusion proteins may differ to some extent between the stably arr-egfP-expressing and the transiently arr-td-rfP611-expressing u2os cells. however, in control experiments using transient transfection of cells with cdnas encoding arr-egfP and arr-td-rfP611 in the same expression vector, the same constitutive cXcr2dependent arrestin redistribution was observed as for the stably transfected cells. furthermore, when investigated at the single cell level, the extent of arrestin accumulation did not consistently correlate with the arrestin expression levels among the individual cells within an image, neither for arr-egfP nor for arr-td-rfP611. therefore, we propose that the threshold for arrestin activation is somewhat reduced for the arr-egfP fusion protein in comparison to arr-td-rfP611. this decreased threshold may possibly be due to a reduced steric hindrance for the arr-egfP chimera with the single egfP tag instead of the tandem dimeric fP label in arr-td-rfP611 of approximately twice the size.
the ec 50 of gro-α in mediating arr-td-rfP611 redistribution, 1.1 nm, was similar to the ec 50 values determined in other hcs assays: 2 to 4 nm for cXcr2 internalization ( Table 1) , 2.2 nm for perK signaling, and 0.9 nm for nfat signaling. 50 these ec 50 values diverge, however, to different extents from previously reported ec 50 values for other cXcr2-dependent signaling events. thus, ec 50 values of gro-α were 30 nm, 18 nm, and 250 nm when ca 2+ release, camP generation, and [ 35 s]gtPγs binding were determined, respectively. 6 of note, we have previously found 35 a broad range of different potencies of mcP-1 in a ccr2b-transfected cho cell line regarding ca 2+ release (ec 50 of 3 nm), [ 35 s]gtPγs binding (ec 50 of 9 nm), ccr2b internalization (ec 50 of 15 nm), erK phosphorylation (ec 50 of 100 pm), and chemotaxis (ec 50 of 1 nm).
these broad ranges of potencies may, for example, be explained by the differences in the kinetic properties of the employed reporter systems, wherein ligand-receptor binding equilibria are typically not established during the course of a transient cellular response (such as arrestin redistribution, ca 2+ release from the endoplasmic reticulum, receptor internalization, and erK or nfat signaling). furthermore, the apparent potency and efficacy of a given ligand in a functional assay are markedly influenced by the presence and abundance of spare receptors present in a given cell for coupling of the receptor to specific g-protein(s), signaling chain(s), and the ultimate assay readout. several aspects of the gPcr internalization mechanism have been thoroughly investigated by others: arrestins mediate the transfer of the gPcr to clathrin-coated pits for subsequent endocytosis 27, 28 and initiate some g-protein-independent processes. 29, 30 in the latter context, arrestin signaling is considered to play a role (e.g., in chemokine receptor-mediated chemotaxis 53 and many other cellular functions through a rapidly expanding list of signaling routes). for cXcr2 in particular, β 2 arrestin was shown to modulate neutrophil chemotaxis and cutaneous wound healing in vivo. 54 When applying a combination of the two cXcr2-dependent arrestin redistribution assays established in this work, cXcr2 ligands may be functionally categorized as agonists, neutral antagonists, or inverse agonists. an even broader parallel profiling of test compounds with regard to receptor desensitization, arrestin redistribution, and g-protein signaling may enable the identification of specific new drugs in the future. 55 examples of gPcr ligands that are "biased" to modulate specific signaling pathways (thus causing so-called ligand-biased signaling) have been reported more frequently in the recent past. [56] [57] [58] the hcs-based observation of test compound-induced arrestin translocation may therefore explain several pharmacological effects beyond receptor desensitization.
